



ANTOINE BARBARI, MD

NEPHROLOGY, HYPERTENSION AND TRANSPLANTATION

Contact Information

Email: barbariantoine@gmail.com

Medical Experience

Medical School	1974-1981
Faculty of Medicine of Montpellier, University of Montpellier, France	
Internship Internal Medicine	1980-1981
University Medical Center, Saint Eloi Montpellier, France	
One year of Residency in Nephrology	1982-1983
University Medical Center, Saint Charles Montpellier, France	
Post-graduate Researcher	1983-1984
Clinical Department of Internal Medicine Nephrology Division, UCI Medical Center, CA	
Research Fellow, Nephrology Division	1984-1986
UCI College of Medicine, Irvine, CA	
Internal Medicine Residency Training	1987-1990
St. Francis Hospital, Evanston, IL	
Nephrology Clinical Fellowship	1990-1991
University of California Los Angeles	

Languages: Arabic (Native), English, French, Spanish

Memberships

Istanbul Declaration Steering Committee Member
Middle East Society of Organ Transplantation, Secretary General
World Academy for Medical and Biomedical and Ethical Sciences. Founding Member
World Academy for Medical and Biomedical and Ethical Sciences. Co-Chair, Scientific Committee
The Transplantation Society, International Ethic Committee Member

The Transplantation Society, Lebanon's country liaison officer
Middle East Society of Organ Transplantation Past Vice-President
International Journal of Organ Transplantation Medicine, Editorial Board Member
Experimental clinical Transplantation, Editorial Board Member
11th Congress of the Asian Society of Transplantation 2009, President
Declaration of Istanbul, Board Council Member
Kidney Disease Improving Global Outcome (KDIGO) Task Force member- Middle East and North Africa
Arab Society of Nephrology and Transplantation
Lebanese Society of Nephrology
Asian Society of Transplantation
International Society of Nephrology
The Transplantation Society
American Society of Nephrology
American College of Physicians
Association of Clinical Faculty - UC Irvine College of Medicine

Publications and Presentations

RESEARCH PAPERS – PEER REVIEWED

A total of 81 Publications and Presentations:

1. **Barbari A.** Posttransplant Hypertension: Multipathogenic Disease Process. *Experimental Clinical Transplantation* April 2013. In press
2. **Barbari A**, Abbas S, and Jaafar M. Approach to kidney Transplantation in Sensitized Potential Transplant Recipients. *Experimental Clinical Transplantation* 2012; (5) : 419-427
3. The Declaration of Istanbul on organ trafficking and transplant tourism. International Summit on Transplant Tourism and Organ Trafficking. *Saudi J Kidney Dis Transpl.* 2010 Jan;21(1):138-47
4. The Declaration of Istanbul on organ trafficking and transplant tourism. International Summit on Transplant Tourism and Organ Trafficking. *Kidney Int.* 2008 Oct;74(7):854-9.
5. Organ trafficking and transplant tourism and commercialism: The Declaration of Istanbul. *Lancet*, July 2008, 372:5-6.
6. The Declaration of Istanbul on Organ Trafficking and Transplant Tourism. *Nephrol Dial Transplant.* 2008 Nov;23(11):3375-80.
7. **Barbari A**, Masri M, Stephan A, Rizk S, Younan F, Bassil N. Time average Cyclosporine maximum level in stable De novo kidney transplant patients: Two years follow-up. *Experimental Clinical Transplantation*, November 2008, Abstract P 161.
8. **Barbari A.** Drug lymphocyte level: New perspective in clinical immunosuppression monitoring. *Annals of Transplantation*, September 2008, Abstract P 45
9. Chammas E, Hussein A, **Barbari A**, Abou Akl M, Hamoui O, Abouzahr L. Regression of cardiac lupus under immunosuppressive therapy. *Circulation* 2008; World Congress of Cardiology, May 2008, Abstract P1349.
10. Stephan A, **Barbari A**, Younan F. Ethical aspects on organ donation. *Experimental Clinical Transplantation* 2007; 2: 633-637.

11. Masri M, Rizk S, **Barbari A**, Stephan A, Kamel G, M Rost. An assay for the determination of Sirolimus levels in the lymphocyte of transplant patients. *Transplant Proc* May 2007; 39 (4):1204-12
12. **Barbari A**, Stephan A and Masri M. Calcineurin inhibitors-free immunosuppression: Risks and benefits. *Saudi J Kid Dis Transplant* March 2007; 18(1):1-23.
13. **Barbari A**, Masri M, Stephan A, Rizk S, Younan F.A novel approach in clinical immunosuppression monitoring: Drug lymphocyte level. *Experimental Clinical Transplantation* 2007; 2: 643-648
14. **Barbari A**, Masri M, Stephan A, Rizk S, Bou Khalil L, Kamel G. Tacrolimus Whole blood Vs Lymphocyte Trough Level: Correlation with the Immune Response. *Experimental and Clinical Transplantation* Dec 2006; vol 4(2): 58.
15. Masri MA, Haberal M, Rizvi A, Stephan A, Bilgin N, Naqvi A, **Barbari A**, Kamel G, Zafar N, Emiroglu R, Colak T, Manzoor K, Matha V, Kamarad V, Andrysek T, Rizk S, Hazime A. Switchability of Neoral with Equoral According to FDA rules and regulations. *Transplant Proc* Sep 2005; 57(7):2988-93
16. **Barbari A**, Stephan A, Masri MA, Kamel G, Karam A, Mourad N, Kilani H, El-Ghoul B. MPA plasma trough Level: Correlation with clinical Outcome. *Experimental and Clinical Transplantation* Dec 2005; 3(2):355-60

LECTURES AND PRESENTATIONS

A Total of 121;

1. 2013- 6th annual Meeting of the Lebanese Society of Critical Care Medicine. Hyponatremia in the Intensive Unit Setting. **Antoine Barbari, MD**
2. 2012- 13th Congress of the Middle East Society of Organ Transplantation, Abu Dhabi. Pharmacogenetics Relevance in Clinical Immunosuppression Monitoring. **Antoine Barbari, MD.**
3. 2012- 13th Congress of the Middle East Society of Organ Transplantation, Abu Dhabi. Antibody-Mediated Rejection: What's New? **Antoine Barbari, MD**
4. 2012- National organization for Organ and Tissue Donation and Transplantation (NOOTDT-Lb) Annual Meeting. The current number of patients on the national waiting List does not reflect the expected national need. **Antoine Barbari, MD.**
5. 2011- Sehat Transplantation Symposium on Implementation steps for Deceased Organ Donation in the UAE, Abu Dhabi. Istanbul Declaration: What it means for the GCC and for the UAE? – **Antoine Barbari, MD**
6. 2011- Fifth update of Nephrology of Lebanese Society of Nephrology. Post transplant hypertension – **Antoine Barbari, MD**
7. 2011 - Annual meeting of Medical Faculty of Medical Sciences at the Lebanese University: Approach to the hypertensive diabetic patient - **Antoine Barbari, MD.**
8. 2011 - Kidney Transplantation Course at American University of Beirut-Cleveland Clinic Foundation: Hypertension in the renal transplant patient - **Antoine Barbari, MD.**
9. 2011 – IXth Annual Jordanian Society of Nephrology meeting: Post-transplant hypertension - **Antoine Barbari, MD.**
10. 2010 - Lebanese American University School of Pharmacy CPD Forum: Pharmacogenetics of Immunosuppressive drugs: What have we learned so far? - **Antoine Barbari, MD.**

11. 2010 Kidney Transplantation Course at American University of Beirut- Cleveland Clinic Foundation: On the necessity of restricting and regulating Live unrelated donation - **Antoine Barbari**, MD
12. 2010 – XIIth Congress of the Middle Society of Organ Transplantation, Tunis-Tunisia: Monitoring Immunosuppressive Therapy: The cell as target - **Antoine Barbari**, MD
13. 2010 - XIIth Congress of the Middle Society of Organ Transplantation, Tunis-Tunisia: Pharmacogenetics of Immunosuppressive drugs - **Antoine Barbari**, MD
14. 2010 - 5th Fresenius Medical Care Forum, Vienna-Austria: Hypertension in Renal Transplantation: Diagnostic and Therapeutic Approaches - **Antoine Barbari**, MD
15. 2010 - XXIXth congress of the Egyptian Society of Nephrology and Transplantation, Cairo-Egypt: CNI Elimination in Kidney Transplantation: Minimization vs. Avoidance - **Antoine Barbari**, MD.